Global Orphan Drugs Market, by Disease Types (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Other Rare Diseases), By Disease Type (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Other Indications), By Distribution Channels (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Published date: Jan 2022
Report ID: 84896
Number of Pages: 277
Format:

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
  - 1.4. Key Analysis
  - 1.5. Key Findings by Major Segments
  - 1.6. Top strategies by Major Players
- 2. Global Orphan Drugs Overview
  - 2.1. Orphan Drugs Dynamics
    2.1.1. Drivers
    2.1.2. Opportunities
    2.1.2. Restraints
    2.1.4. Challenges
  - 2.2. Macro-economic Factors
  - 2.3. Regulatory Framework
  - 2.4. Market Investment Feasibility Index
  - 2.5. PEST Analysis
  - 2.6. PORTER’S Five Force Analysis
  - 2.7. Drivers & Restraints Impact Analysis
  - 2.8. Industry Chain Analysis
  - 2.9. Cost Structure Analysis
  - 2.10. Marketing Strategy
  - 2.11. Russia-Ukraine War Impact Analysis
  - 2.12. Opportunity Map Analysis
  - 2.13. Market Competition Scenario Analysis
  - 2.14. Product Life Cycle Analysis
  - 2.15. Opportunity Orbits
  - 2.16. Manufacturer Intensity Map
  - 2.17. Major Companies sales by Value & Volume
- 3. Global Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 3.1. Global Orphan Drugs Analysis, 2016-2021
  - 3.2. Global Orphan Drugs Opportunity and Forecast, 2023-2032
  - 3.3. Global Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    3.3.1. Global Orphan Drugs Analysis by Disease Types: Introduction
    3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    3.3.3. Oncologic Diseases
    3.3.4. Metabolic Diseases
    3.3.5. Hematologic and Immunologic Diseases
    3.3.6. Infectious Diseases
    3.3.7. Neurologic Diseases
    3.3.8. Other Rare Diseases
  - 3.4. Global Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    3.4.1. Global Orphan Drugs Analysis by Indications: Introduction
    3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    3.4.3. Non-Hodgkin Lymphoma
    3.4.4. Acute Myeloid Leukemia
    3.4.5. Cystic Fibrosis
    3.4.6. Glioma
    3.4.7. Pancreatic Cancer
    3.4.8. Ovarian Cancer
    3.4.9. Multiple Myeloma
    3.4.10. Duchenne Muscular Dystrophy
    3.4.11. Graft vs Host Disease
    3.4.12. Renal Cell Carcinoma
    3.4.13. Other Indications
  - 3.5. Global Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    3.5.1. Global Orphan Drugs Analysis by Distribution Channels: Introduction
    3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    3.5.3. Hospital Pharmacies
    3.5.4. Online Pharmacies
    3.5.5. Retail Pharmacies
    3.5.6. Other Distribution Channels
- 4. North America Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 4.1. North America Orphan Drugs Analysis, 2016-2021
  - 4.2. North America Orphan Drugs Opportunity and Forecast, 2023-2032
  - 4.3. North America Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    4.3.1. North America Orphan Drugs Analysis by Disease Types: Introduction
    4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    4.3.3. Oncologic Diseases
    4.3.4. Metabolic Diseases
    4.3.5. Hematologic and Immunologic Diseases
    4.3.6. Infectious Diseases
    4.3.7. Neurologic Diseases
    4.3.8. Other Rare Diseases
  - 4.4. North America Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    4.4.1. North America Orphan Drugs Analysis by Indications: Introduction
    4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    4.4.3. Non-Hodgkin Lymphoma
    4.4.4. Acute Myeloid Leukemia
    4.4.5. Cystic Fibrosis
    4.4.6. Glioma
    4.4.7. Pancreatic Cancer
    4.4.8. Ovarian Cancer
    4.4.9. Multiple Myeloma
    4.4.10. Duchenne Muscular Dystrophy
    4.4.11. Graft vs Host Disease
    4.4.12. Renal Cell Carcinoma
    4.4.13. Other Indications
  - 4.5. North America Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    4.5.1. North America Orphan Drugs Analysis by Distribution Channels: Introduction
    4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    4.5.3. Hospital Pharmacies
    4.5.4. Online Pharmacies
    4.5.5. Retail Pharmacies
    4.5.6. Other Distribution Channels
  - 4.6. North America Orphan Drugs Analysis, Opportunity and Forecast, By Country , 2016-2032
    4.6.1. North America Orphan Drugs Analysis by Country : Introduction
    4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    4.6.2.1. U.S.
    4.6.2.2. Canada
    4.6.2.3. Mexico
- 5. Europe Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 5.1. Europe Orphan Drugs Analysis, 2016-2021
  - 5.2. Europe Orphan Drugs Opportunity and Forecast, 2023-2032
  - 5.3. Europe Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    5.3.1. Europe Orphan Drugs Analysis by Disease Types: Introduction
    5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    5.3.3. Oncologic Diseases
    5.3.4. Metabolic Diseases
    5.3.5. Hematologic and Immunologic Diseases
    5.3.6. Infectious Diseases
    5.3.7. Neurologic Diseases
    5.3.8. Other Rare Diseases
  - 5.4. Europe Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    5.4.1. Europe Orphan Drugs Analysis by Indications: Introduction
    5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    5.4.3. Non-Hodgkin Lymphoma
    5.4.4. Acute Myeloid Leukemia
    5.4.5. Cystic Fibrosis
    5.4.6. Glioma
    5.4.7. Pancreatic Cancer
    5.4.8. Ovarian Cancer
    5.4.9. Multiple Myeloma
    5.4.10. Duchenne Muscular Dystrophy
    5.4.11. Graft vs Host Disease
    5.4.12. Renal Cell Carcinoma
    5.4.13. Other Indications
  - 5.5. Europe Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    5.5.1. Europe Orphan Drugs Analysis by Distribution Channels: Introduction
    5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    5.5.3. Hospital Pharmacies
    5.5.4. Online Pharmacies
    5.5.5. Retail Pharmacies
    5.5.6. Other Distribution Channels
  - 5.6. Europe Orphan Drugs Analysis, Opportunity and Forecast, By Country , 2016-2032
    5.6.1. Europe Orphan Drugs Analysis by Country : Introduction
    5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    5.6.2.1. U.K.
    5.6.2.2. Germany
    5.6.2.3. France
    5.6.2.4. Spain
    5.6.2.5. Italy
    5.6.2.6. Russia
    5.6.2.7. Rest of Europe
- 6. Asia-Pacific Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 6.1. Asia-Pacific Orphan Drugs Analysis, 2016-2021
  - 6.2. Asia-Pacific Orphan Drugs Opportunity and Forecast, 2023-2032
  - 6.3. Asia-Pacific Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    6.3.1. Asia-Pacific Orphan Drugs Analysis by Disease Types: Introduction
    6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    6.3.3. Oncologic Diseases
    6.3.4. Metabolic Diseases
    6.3.5. Hematologic and Immunologic Diseases
    6.3.6. Infectious Diseases
    6.3.7. Neurologic Diseases
    6.3.8. Other Rare Diseases
  - 6.4. Asia-Pacific Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    6.4.1. Asia-Pacific Orphan Drugs Analysis by Indications: Introduction
    6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    6.4.3. Non-Hodgkin Lymphoma
    6.4.4. Acute Myeloid Leukemia
    6.4.5. Cystic Fibrosis
    6.4.6. Glioma
    6.4.7. Pancreatic Cancer
    6.4.8. Ovarian Cancer
    6.4.9. Multiple Myeloma
    6.4.10. Duchenne Muscular Dystrophy
    6.4.11. Graft vs Host Disease
    6.4.12. Renal Cell Carcinoma
    6.4.13. Other Indications
  - 6.5. Asia-Pacific Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    6.5.1. Asia-Pacific Orphan Drugs Analysis by Distribution Channels: Introduction
    6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    6.5.3. Hospital Pharmacies
    6.5.4. Online Pharmacies
    6.5.5. Retail Pharmacies
    6.5.6. Other Distribution Channels
  - 6.6. Asia-Pacific Orphan Drugs Analysis, Opportunity and Forecast, By Country , 2016-2032
    6.6.1. Asia-Pacific Orphan Drugs Analysis by Country : Introduction
    6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    6.6.2.1. China
    6.6.2.2. Japan
    6.6.2.3. South Korea
    6.6.2.4. India
    6.6.2.5. Rest of Asia-Pacific
- 7. South America Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 7.1. South America Orphan Drugs Analysis, 2016-2021
  - 7.2. South America Orphan Drugs Opportunity and Forecast, 2023-2032
  - 7.3. South America Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    7.3.1. South America Orphan Drugs Analysis by Disease Types: Introduction
    7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    7.3.3. Oncologic Diseases
    7.3.4. Metabolic Diseases
    7.3.5. Hematologic and Immunologic Diseases
    7.3.6. Infectious Diseases
    7.3.7. Neurologic Diseases
    7.3.8. Other Rare Diseases
  - 7.4. South America Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    7.4.1. South America Orphan Drugs Analysis by Indications: Introduction
    7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    7.4.3. Non-Hodgkin Lymphoma
    7.4.4. Acute Myeloid Leukemia
    7.4.5. Cystic Fibrosis
    7.4.6. Glioma
    7.4.7. Pancreatic Cancer
    7.4.8. Ovarian Cancer
    7.4.9. Multiple Myeloma
    7.4.10. Duchenne Muscular Dystrophy
    7.4.11. Graft vs Host Disease
    7.4.12. Renal Cell Carcinoma
    7.4.13. Other Indications
  - 7.5. South America Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    7.5.1. South America Orphan Drugs Analysis by Distribution Channels: Introduction
    7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    7.5.3. Hospital Pharmacies
    7.5.4. Online Pharmacies
    7.5.5. Retail Pharmacies
    7.5.6. Other Distribution Channels
  - 7.6. South America Orphan Drugs Analysis, Opportunity and Forecast, By Country , 2016-2032
    7.6.1. South America Orphan Drugs Analysis by Country : Introduction
    7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    7.6.2.1. Brazil
    7.6.2.2. Argentina
    7.6.2.3. Rest of South America
- 8. Middle East and Africa Orphan Drugs Analysis, Opportunity and Forecast, 2016-2032
  - 8.1. Middle East and Africa Orphan Drugs Analysis, 2016-2021
  - 8.2. Middle East and Africa Orphan Drugs Opportunity and Forecast, 2023-2032
  - 8.3. Middle East and Africa Orphan Drugs Analysis, Opportunity and Forecast, By Disease Types, 2016-2032
    8.3.1. Middle East and Africa Orphan Drugs Analysis by Disease Types: Introduction
    8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Types, 2016-2032
    8.3.3. Oncologic Diseases
    8.3.4. Metabolic Diseases
    8.3.5. Hematologic and Immunologic Diseases
    8.3.6. Infectious Diseases
    8.3.7. Neurologic Diseases
    8.3.8. Other Rare Diseases
  - 8.4. Middle East and Africa Orphan Drugs Analysis, Opportunity and Forecast, By Indications, 2016-2032
    8.4.1. Middle East and Africa Orphan Drugs Analysis by Indications: Introduction
    8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indications, 2016-2032
    8.4.3. Non-Hodgkin Lymphoma
    8.4.4. Acute Myeloid Leukemia
    8.4.5. Cystic Fibrosis
    8.4.6. Glioma
    8.4.7. Pancreatic Cancer
    8.4.8. Ovarian Cancer
    8.4.9. Multiple Myeloma
    8.4.10. Duchenne Muscular Dystrophy
    8.4.11. Graft vs Host Disease
    8.4.12. Renal Cell Carcinoma
    8.4.13. Other Indications
  - 8.5. Middle East and Africa Orphan Drugs Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
    8.5.1. Middle East and Africa Orphan Drugs Analysis by Distribution Channels: Introduction
    8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
    8.5.3. Hospital Pharmacies
    8.5.4. Online Pharmacies
    8.5.5. Retail Pharmacies
    8.5.6. Other Distribution Channels
  - 8.6. Middle East and Africa Orphan Drugs Analysis, Opportunity and Forecast, By Country , 2016-2032
    8.6.1. Middle East and Africa Orphan Drugs Analysis by Country : Introduction
    8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    8.6.2.1. GCC
    8.6.2.2. Israel
    8.6.2.3. South Africa
    8.6.2.4. Rest of MEA
- 9. Global Orphan Drugs Analysis, Opportunity and Forecast, By Region , 2016-2032
  - 9.1. Global Orphan Drugs Analysis by Region : Introduction
  - 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
    9.2.1. North America
    9.2.2. Europe
    9.2.3. Asia-Pacific
    9.2.4. South America
    9.2.5. Middle East and Africa
- 10. Global Orphan Drugs Competitive Landscape, Market Share Analysis, and Company Profiles
  - 10.1. Market Share Analysis
  - 10.2. Company Profiles
  - 10.3. Bayer HealthCare Pharmaceuticals Inc.
    10.3.1. Company Overview
    10.3.2. Financial Highlights
    10.3.3. Product Portfolio
    10.3.4. SWOT Analysis
    10.3.5. Key Strategies and Developments
  - 10.4. Vertex Pharmaceuticals
    10.4.1. Company Overview
    10.4.2. Financial Highlights
    10.4.3. Product Portfolio
    10.4.4. SWOT Analysis
    10.4.5. Key Strategies and Developments
  - 10.5. Merck & Co. Inc.
    10.5.1. Company Overview
    10.5.2. Financial Highlights
    10.5.3. Product Portfolio
    10.5.4. SWOT Analysis
    10.5.5. Key Strategies and Developments
  - 10.6. Alexion Pharmaceutical Inc.
    10.6.1. Company Overview
    10.6.2. Financial Highlights
    10.6.3. Product Portfolio
    10.6.4. SWOT Analysis
    10.6.5. Key Strategies and Developments
  - 10.7. Boehringer Ingelheim GmbH
    10.7.1. Company Overview
    10.7.2. Financial Highlights
    10.7.3. Product Portfolio
    10.7.4. SWOT Analysis
    10.7.5. Key Strategies and Developments
  - 10.8. Amgen Inc.
    10.8.1. Company Overview
    10.8.2. Financial Highlights
    10.8.3. Product Portfolio
    10.8.4. SWOT Analysis
    10.8.5. Key Strategies and Developments
  - 10.9. Biogen Idec
    10.9.1. Company Overview
    10.9.2. Financial Highlights
    10.9.3. Product Portfolio
    10.9.4. SWOT Analysis
    10.9.5. Key Strategies and Developments
  - 10.10. Actelion Pharmaceuticals Ltd.
    10.10.1. Company Overview
    10.10.2. Financial Highlights
    10.10.3. Product Portfolio
    10.10.4. SWOT Analysis
    10.10.5. Key Strategies and Developments
  - 10.11. AstraZeneca Plc
    10.11.1. Company Overview
    10.11.2. Financial Highlights
    10.11.3. Product Portfolio
    10.11.4. SWOT Analysis
    10.11.5. Key Strategies and Developments
  - 10.12. Janssen Biotech Inc.
    10.12.1. Company Overview
    10.12.2. Financial Highlights
    10.12.3. Product Portfolio
    10.12.4. SWOT Analysis
    10.12.5. Key Strategies and Developments
  - 10.13. Others.
    10.13.1. Company Overview
    10.13.2. Financial Highlights
    10.13.3. Product Portfolio
    10.13.4. SWOT Analysis
    10.13.5. Key Strategies and Developments
- 11. Assumptions and Acronyms
- 12. Research Methodology
- 13. Contact
"
- List of Figures
  - Figure 1: Global Orphan Drugs Revenue (US$ Mn) Market Share by Disease Types in 2022
  - Figure 2: Global Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 3: Global Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 4: Global Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 5: Global Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 6: Global Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 7: Global Orphan Drugs Revenue (US$ Mn) Market Share by Region in 2022
  - Figure 8: Global Orphan Drugs Market Attractiveness Analysis by Region, 2016-2032
  - Figure 9: Global Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 10: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Figure 11: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 12: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 13: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 14: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Figure 15: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 16: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 17: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 18: Global Orphan Drugs Market Share Comparison by Region (2016-2032)
  - Figure 19: Global Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 20: Global Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 21: Global Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 22: North America Orphan Drugs Revenue (US$ Mn) Market Share by Disease Typesin 2022
  - Figure 23: North America Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 24: North America Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 25: North America Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 26: North America Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 27: North America Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 28: North America Orphan Drugs Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 29: North America Orphan Drugs Market Attractiveness Analysis by Country, 2016-2032
  - Figure 30: North America Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 31: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 32: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 33: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 34: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 35: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 36: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 37: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 38: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 39: North America Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Figure 40: North America Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 41: North America Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 42: North America Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 43: Europe Orphan Drugs Revenue (US$ Mn) Market Share by Disease Typesin 2022
  - Figure 44: Europe Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 45: Europe Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 46: Europe Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 47: Europe Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 48: Europe Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 49: Europe Orphan Drugs Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 50: Europe Orphan Drugs Market Attractiveness Analysis by Country, 2016-2032
  - Figure 51: Europe Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 52: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 53: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 54: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 55: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 56: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 57: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 58: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 59: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 60: Europe Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Figure 61: Europe Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 62: Europe Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 63: Europe Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 64: Asia-Pacific Orphan Drugs Revenue (US$ Mn) Market Share by Disease Typesin 2022
  - Figure 65: Asia-Pacific Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 66: Asia-Pacific Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 67: Asia-Pacific Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 68: Asia-Pacific Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 69: Asia-Pacific Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 70: Asia-Pacific Orphan Drugs Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 71: Asia-Pacific Orphan Drugs Market Attractiveness Analysis by Country, 2016-2032
  - Figure 72: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 73: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 74: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 75: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 76: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 77: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 78: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 79: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 80: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 81: Asia-Pacific Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Figure 82: Asia-Pacific Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 83: Asia-Pacific Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 84: Asia-Pacific Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 85: South America Orphan Drugs Revenue (US$ Mn) Market Share by Disease Typesin 2022
  - Figure 86: South America Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 87: South America Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 88: South America Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 89: South America Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 90: South America Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 91: South America Orphan Drugs Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 92: South America Orphan Drugs Market Attractiveness Analysis by Country, 2016-2032
  - Figure 93: South America Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 94: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 95: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 96: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 97: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 98: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 99: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 100: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 101: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 102: South America Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Figure 103: South America Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 104: South America Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 105: South America Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Figure 106: Middle East and Africa Orphan Drugs Revenue (US$ Mn) Market Share by Disease Typesin 2022
  - Figure 107: Middle East and Africa Orphan Drugs Market Attractiveness Analysis by Disease Types, 2016-2032
  - Figure 108: Middle East and Africa Orphan Drugs Revenue (US$ Mn) Market Share by Indicationsin 2022
  - Figure 109: Middle East and Africa Orphan Drugs Market Attractiveness Analysis by Indications, 2016-2032
  - Figure 110: Middle East and Africa Orphan Drugs Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
  - Figure 111: Middle East and Africa Orphan Drugs Market Attractiveness Analysis by Distribution Channels, 2016-2032
  - Figure 112: Middle East and Africa Orphan Drugs Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 113: Middle East and Africa Orphan Drugs Market Attractiveness Analysis by Country, 2016-2032
  - Figure 114: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Figure 115: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 116: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Figure 117: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Figure 118: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Figure 119: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 120: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Figure 121: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Figure 122: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Figure 123: Middle East and Africa Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Figure 124: Middle East and Africa Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Figure 125: Middle East and Africa Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Figure 126: Middle East and Africa Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  "
- List of Tables
  - Table 1: Global Orphan Drugs Market Comparison by Disease Types (2016-2032)
  - Table 2: Global Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 3: Global Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 4: Global Orphan Drugs Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 5: Global Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 6: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 7: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 8: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 9: Global Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 10: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Table 11: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 12: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 13: Global Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 14: Global Orphan Drugs Market Share Comparison by Region (2016-2032)
  - Table 15: Global Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 16: Global Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 17: Global Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Table 18: North America Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 19: North America Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 20: North America Orphan Drugs Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 21: North America Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 22: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 23: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 24: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 25: North America Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 26: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 27: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 28: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 29: North America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 30: North America Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Table 31: North America Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 32: North America Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 33: North America Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Table 34: Europe Orphan Drugs Market Comparison by Disease Types (2016-2032)
  - Table 35: Europe Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 36: Europe Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 37: Europe Orphan Drugs Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 38: Europe Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 39: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 40: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 41: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 42: Europe Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 43: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 44: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 45: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 46: Europe Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 47: Europe Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Table 48: Europe Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 49: Europe Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 50: Europe Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Table 51: Asia-Pacific Orphan Drugs Market Comparison by Disease Types (2016-2032)
  - Table 52: Asia-Pacific Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 53: Asia-Pacific Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 54: Asia-Pacific Orphan Drugs Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 55: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 56: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 57: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 58: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 59: Asia-Pacific Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 60: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 61: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 62: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 63: Asia-Pacific Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 64: Asia-Pacific Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Table 65: Asia-Pacific Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 66: Asia-Pacific Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 67: Asia-Pacific Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Table 68: South America Orphan Drugs Market Comparison by Disease Types (2016-2032)
  - Table 69: South America Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 70: South America Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 71: South America Orphan Drugs Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 72: South America Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 73: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 74: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 75: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 76: South America Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 77: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 78: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 79: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 80: South America Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 81: South America Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Table 82: South America Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 83: South America Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 84: South America Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
  - Table 85: Middle East and Africa Orphan Drugs Market Comparison by Disease Types (2016-2032)
  - Table 86: Middle East and Africa Orphan Drugs Market Comparison by Indications (2016-2032)
  - Table 87: Middle East and Africa Orphan Drugs Market Comparison by Distribution Channels (2016-2032)
  - Table 88: Middle East and Africa Orphan Drugs Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 89: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) (2016-2032)
  - Table 90: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 91: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Disease Types (2016-2032)
  - Table 92: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Indications (2016-2032)
  - Table 93: Middle East and Africa Orphan Drugs Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
  - Table 94: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 95: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Disease Types (2016-2032)
  - Table 96: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Indications (2016-2032)
  - Table 97: Middle East and Africa Orphan Drugs Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
  - Table 98: Middle East and Africa Orphan Drugs Market Share Comparison by Country (2016-2032)
  - Table 99: Middle East and Africa Orphan Drugs Market Share Comparison by Disease Types (2016-2032)
  - Table 100: Middle East and Africa Orphan Drugs Market Share Comparison by Indications (2016-2032)
  - Table 101: Middle East and Africa Orphan Drugs Market Share Comparison by Distribution Channels (2016-2032)
- Bayer HealthCare Pharmaceuticals Inc.
- Vertex Pharmaceuticals
- Merck & Co. Inc.
- Alexion Pharmaceutical Inc.
- Boehringer Ingelheim GmbH
- Amgen Inc.
- Biogen Idec
- Actelion Pharmaceuticals Ltd.
- AstraZeneca Plc Company Profile
- Janssen Biotech Inc.
- Others.
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $5,999 $2,999 USD / per unit save 50%	Multi User $7,999 $3,499 USD / per unit save 55%	Corporate User $12,999 $4,499 USD / per unit save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 2,999)	Buy Now ($ 3,499)	Buy Now ($ 4,499)